Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If someone asked me, 'Why should I buy Amarin shares at $1.05?' I'd have answer. I'd say 'they still own the same successful product which hasn't even begun to capture its true market potential and now we have a CEO who knows how to get it done.' So be it a child being given 10 shares for his birthday or a 100 shares or 10,000 or 100,000 shares, true longs on the IHUB owe to themselves to invite newbies to join us in this exciting journey to greatness. Denner's new team led by Holt have already been making all the necessary fiscal moves, and you can bank on them going hard and fast to recapture Italy and Germany, and we all hope France. No doubt Latin America is next leading with Brazil or Mexico.
I know I can get cranky, but whether I buy 1 share or 10,000, my heart/head are still there. We all know Holt wants nothing less than $15 and likely much more and his own money is where his mouth is. I say, 'Rally the troops! Stand our ground shoulder to shoulder! And never, never give up!
IMO, Amarin can always go lower and I'll be buying because it's already significantly under-valued until that time much bigger pockets move in, start buying millions of shares, driving up the pps, and doing it purposely, because that's how it works in small biotech land. We all know the product Vascepa/Vazkepa is effective, actually quite effective beyond usual dreams when by taking it one is gaining years of health, and it is very safe. To think the next newer version is coming is totally exciting as it builds out the value to the franchise. Choosing Denner over KM et al has gotten us Holt, and Holt could run circles around KM as a CEO. Someone looking for a hot biotech spec whose never bought before has the golden opportunity right now to buy those 5... 10... 20... 30,000 with the increased likelihood of seeing at least $10 pps in 1-3 yrs... that's an amazing way to build wealth.
In a smaller account of mine I've increased to 10,000 shares which may not seem like much to you, but when Holt / Denner work to get Amarin above $10/share (a firm belief I have) that will be $100,000 for a very small risk of money. This account is also a very small fraction of my other activity, but I prefer not to share that as of now. And why I responded was because you're a bit pompous, or cocky, and honestly people have different means ($$$). I'm very fortunate because I'm extremely pleased that Holt was the correct choice. Anyway, all the best as I think back I once bought 100,000 shares in an oil spec at 0.20c that eventually hit $10.
Quadrupled position in one account. In it to win it with Holt & Denner!!! I see this taking off very soon! Why? Holt's extremely strategic and with lots of skin in the game, he's wining and dining the French!!! I hear Italy is already back in talks too. I hear lots of things like the rest of you! Thing is, just wait until the market digests --
Vblastepa!!!
Tripled my one account position today. It's a free gift at this level. Lining up with Holt.
I feeling like Amarin is heading for a hundred plus pps with all this excitement over EPAMAX!!!
As Amarin has revealed in the WO application the far-ranging potential uses for Vascepa have only just begun as they now assert "to treat various diseases including cardiopulmonary diseases, renal diseases, neurological diseases, and cancer." This is why the current Alzheimer's study is important because it could reveal Vascepa-Version-2's formulation potential which is why I'm a longer-than-usual term investor. Some time back, Dr. Bhatt et al published a paper exploring how Vascepa may address multiple diseases far beyond CVD. Italy and Germany have revealed they'd rather save money than save lives even though Vazkepa would lower overall CVD costs. Meanwhile, how will Holt convince WS to go-long on Amarin and crush the short day-trading? Amarin's research pipeline is under lock n key scared no doubt by the previous patent debacle. Stupid me thinks 'increasing revenue' is the only path forward unless Vascepa's potential use in Alzheimer's is more than promising via the current clinical study, but meanwhile, Amarin's slashed sales staff which implies non-productivity on a wide scale as it also implies Amarin lacks the influence BP has, so what is Holt up to? Well, I'm just musing and still hoping I made a good investment that will pay off in five or so years. Whatever... right?
I like Holt, a lot, but in a business-only way. Billionaire was an expression, but I have every belief Holt wants the highest pps possible. He has now fulfilled his intent to buy shares on the open market; he is now ONE OF US. I suspect Italy people may see some layoffs, no thanks to Laurent fumbling along with KM. My major concern is France. We now need France and I can only imagine how Holt is focusing, and how he is trying to clean up the Laurent KM fumble of Germany and now Italy; Italy's hirings which I documented mimic the German debacle; no wonder Laurent was fired.
Meanwhile we're seeing 2nd generation Vascepa rising out of research. We all knew it was there, but now it's coming. Amarin's managing the development expense, but it's coming, and it's exciting if you have a long-term horizon (or BO). Handled correctly, Amarin could revisit double-digits very soon.
Think. Holt has risked $300,000 for a multi-billion payday should he turn Amarin around. Millionaires could be created if they bet lesser sums like $10,000 at $1.03. The question then becomes, Do you think Holt can do it? Just do the simple math on a $10 pps. Wow!
I wasn't stopped once (Good grief someone tell me Lovaza... are you kidding me? And fibrates?)
Let the light of Vascepa outshines.
PharmacyDUD wants to spread his you-know-what because he had a free ticket until his short gain exposed him
He's toxic. Stay away from this phony baloney. Fibrates? Are you even serious? Lovaza? Oh come on now!
pharmacyKID REALLY wants us to believe FIBRATES? Are you joking? Good grief. Even KM is laughing at him.
Lovaza has a rotten LDL side effect, and fibrates? Are you even kidding me?
There's a lot of pony-boys on the Amarin board. Please sell and go away. Fibrates shouldn't even be part of the discussion.
Anyone including ponyPharmacy promoting Lovaza is A SHORT.
That's baloney
It's refreshing to read the truth. PharmacyDUDE is pompous and I suspect SHORT for why else does he/she show up? Fibrates and Lovaza aren't even in the same league as Vascepa. Many suspect he's a trolling Adam F., no joke.
pharmacyDUDE
Ok, so you have no medical background or knowledge. Got it
Fibrates? Lovaza? What SHORT PLANET do you practice voodoo?
Utter nonsense.
Fibrates are typically untolerable and Lovaza raises LDL. Vascepa is safe and effective and is a long term solution to adding life.
Not that anyone seems to care, but I offered two posts on employees at Amarin in Ireland and Europe. One takeaway for me was seeing Amarin's confidence they had Italy in the bag when you look at hirees--wonder if they'll be laid off. Any takeaway is the lengthy lawyer list in Ireland, business types, no foot to ground sales I found yet, and I also came across the massive list of names laid off in America. I also saw how they fired Laurent who puts a real spin on his Linkin site. Given enough time it would be fascinating to see how many employees are where?, and for what? as I'm yet to really come across "research" which it looks like Mochida is doing on behalf on Amarin yet there does seem to be activitiy elsewhere. Also looks like Zwick works from home in NC. They also seem to have a lot of employees in Switzerland. Great patent finds and thanks SS teacher for weekly scripts. Cheers everyone!!!
More Amarin European faces in Ireland...
Franco Vasciminno Director of Finance at Amarin Corporation Ireland read
Conor Dalton VP Finance at Amarin Corporation Ireland read
Zoe Chatten Executive Director, Legal at Amarin Pharmaceuticals Ireland Limited Ireland read
Donna Naughton Associate Director, Legal Counsel at Amarin Pharmaceuticals Ireland Limited Ireland read
Sarah Ryan Senior Legal Counsel, Amarin Corporation Ireland read
Elizabeth Collins Vice President, Head of Global Quality at Amarin Corporation Ireland read
Claire Cronin Associate Director, Quality Assurance at Amarin Pharmaceuticals County Westmeath, Ireland read
Lisa Gray Senior Quality Specialist at Amarin Dublin, County Dublin, Ireland read
Shane O'Rourke Senior Supply Chain Manager Ireland read
Amarin's European Faces you may not know about...
Tamara Barghout Vice President Marketing Head Europe Switzerland read
Roberto Bergonzi Marketing Director Italy at Amarin Milan, Lombardy, Italy read
Flavia Macrì Marketing Manager presso Amarin Corporation Rome, Latium, Italy read
Christos Papadopoulos Vice President - General Manager Central Eastern Europe Region at Amarin Corporation Zug, Switzerland read
Benoît Donze pricing, contracting and tender management expert Zurich, Switzerland read
Marc-Sebastian Goebel Executive Director - Head of Compliance & Data Privacy Europe - be bold! everything is possible...create & shape! Zug, Switzerland read
Henrik Asmussen VP & General Manager Mid-Europe and Nordics at Amarin Corporation Zug, Switzerland read
Viraj Bhatti, MBA Commercial Excellence | Digital Zurich, Switzerland read
Olivier Delannoy VP, Commercial Excellence and Business Operations, Europe Brussels Metropolitan Area read
Beltrán Rodríguez Rodríguez Senior Manager Finance at Amarin Corporation Zug, Switzerland read
When was Laurant (EU) fired?
Spain is smarter than Italy
The Uk is smarter than Germany
France? It’s a coin toss, but know this: from China to Asian markets, Australia, New Zealand, Israel are all lining up
Here comes Brazil
I personally think a side effect of statins correlates to the rise of brain disorders due to robbing the brain of necessary cholesterol. It's as a friend who just finish immunotherapy Keytruda: "Don't think there aren't side effects. There are." Unfortunately modern medicine operates under 'standard of care' which just means the money and not necessarily the science drives what doctors prescribe. So far IPE doesn't seem to have a nasty side effect which makes it unique. A lot of people, myself included cannot tolerate statins--thus, IPE means even more to us.
My point? There is a HUGE UNTAPPED market of statin-intolerant people who would greatly benefit from Vascepa/Vazkepa.
Many countries like Philippines use FDA approval, so sales can be launched quickly as they register. China, now Asia plus
I think Amarin’s quickly becoming a turnaround story
IPA = Icosapent Ethyl. I suddenly understand why our SS teacher Captain drinks so much beer.
He's an IPA guy! Cheers!
I absolutely agree Amarin doesn't need a generic, but instead can offer the high quality name-brand against inferior generics at the price point. This is why Teva knows it's losing the war.
Alex and Goldman Sachs, that will change everything.
Holding a bag of gold is how I see it. My only investment error was not knowing about the Du situation. My fault, I simply was unaware. But as fate would have it, I got in at a much lower price, but then again, blew it not selling in the mid-20's--being greedy. Meanwhile no loss because I haven't sold except once when I lowered my basis. It's no secret I'm glad to have Alex on board and I love the Holt pick. What will turn the pps up? IMO, Goldman Sachs issuing a buy and a $10 target--IMO.
I'm content to wait another 2 years for the $20s
Respectfully US-partnering makes no sense.
Amarin already outstrips all the other generics in sales, so why would they offer to share because they would end up losing revenue in that kind of arrangement? The Vascepa brand is already holding its own and by lowering its price Amarin is putting the squeeze on generics. If Sunday School beer-drinking teacher is correct, Amarin may even be recapturing market share! Partner with Teva? No way!!! Never!!!
No, for a BO, Amarin must retain the US market as part of a deal: All or nothing. The more lucrative Amarin's hold on the US market the better for determining corporate valuation. By using its brand price to beat back generics is why Amarin hasn't introduced its own generic yet--why not prescribe and purchase the brand-drug if a lesser-generic costs about the same?
The last thing we want is for Amarin to get into bed with a generic company.
Finally, the reason Alex went lean in the US is obvious; that's what you do when plan to sell a company; you strip out the bacon (fat). BP already has their sales structure selling multiple CVD drugs, so they have no interest in Amarin's sales force nor is it of value to them. If you watch what Alex is doing in Europe, there too Amarin is going lean and mean because the same situation applies there too.
Why Amarin isn't sold yet is obvious. The approvals in Europe (particularly the top countries) are necessary for Alex to drive the BO price. Probably BP has already floated a BO, but at a lower than acceptable price. We need the UK, Spain, France, Italy, even Germany. Bank on Holt being laser focused now on France and Italy even Germany.
CEO Holt steps it up: “The positive recommendation for VAZKEPA in Spain is an important step for the thousands of cardiovascular patients who now have access to a new, innovative treatment option to reduce their cardiovascular risk based on the robust clinical data and evidence from the REDUCE-IT study,” said Patrick Holt, President and CEO of Amarin. “Our team in Spain will now be laser-focused on supporting efforts to reach healthcare professionals and drive awareness and adoption of this important new treatment for patients. I look forward to our launch efforts to accelerate growth in this important market.”
It's a new day at Amarin and in other global markets.
Alzheimer's: to be perfectly I do not see EPA ever being a 'cure', but rather, a 'preventative as in prolonging life' like in CVD. The difference is critical to the conversation and other's like me probably think the same. EPA most likely is a 'preventative to a measurable degree in years' which 'prolongs the onset of the disease' as it does in CVD. I do not however think it will cure someone with Alzheimer's though it may pro-long the onset of the disease.
Thank you in advance. Italy's likely next, then France 2024. Germany, do we care they let their citizens die without hope?
Why I muted Meowza or however it's spelled.
Honestly I got tired of viewing his/her creepy pictures and lame-brain comments I never found the least bit humorous. I'm starting to add others too like that Pharma-dude who imo doesn't know the first thing about biotechs. I do enjoy beer drinking SS teacher Captain.
Why I muted Kiwi--
He/she is not someone I'd enjoy sharing coffee on a Monday morning...
He/she is also characteristically negative on Amarin's pps outcome and I really don't live for that short-nonsense...
He/she makes outlandish comments... well, we differ so our radar screen is better without Kiwi and others.
I'm here to stand behind Alex, continue our dialogue, and watch how new hire Holt grows the firm. thanks Alex!
Captain downing beer while teaching Sunday School, you are a hero here on IHUB. No need to apologize because you're earlier projection can be compared with the 'actual' revenue and then allows all of us to see the dramatic difference. In fact it's your hard work which convinces me Alex was already at work asking why we were paying for a sales force in the USA when the generics were not. Thus we just lower the price and cut out the sales staff and move in a different direction.
I still maintain $15 is the bar Alex recognizes will make "all investors" happy, but it's not a hard and fast number--could be a little lower or even higher depending on future variables. In any case, I imagine Captain supplying beer in Sunday School--he must be very popular.
$15 BO Benchmark: Alex has put it out there
I entirely agree with golfstud who wrote:
"IMO the $15 number for full vestment of the new CEO is a number intentionally put out there as that is what Denner feels the company is worth at a minimum if the new CEO does a good job and he should be rewarded if that number is achieved.
I also believe Denner feels the company is worth more than $15 if certain things fall our way such as a positive Brave study
$5 really???? Denner bought in at $4 and said the company is highly undervalued at that number. No way he was thinking $5 was the return.
I know the response will be that since he bought in the stock has gone to $1. Yes that is true but he needed to make his move to get control of the company and the move was then as time is of the essence."
I remain convinced from reading the pr that is the base price $15 around $6B assuming Holt can deliver.
No it's not. $15pps is the price Alex believes will satisfy all shareholders. Conversation ended.
BO bar set at $15 pps "for all shareholders"
Amazing how people are either unable to correctly read or just plain lie. Holt is here and shorts have been put on notice. If Holt gets it over $15, the more money he makes to the glee of shareholders.
Today was not only a "For Sale" at $6B plus... it give HFs every reason to jump on board... run the stock up... cash in... make tons of money.... and do it fast.
$15pps IS the base target. "...the vast majority of Mr. Holt’s total target compensation is tied to the creation of shareholder value....thus, aligned with the interest of shareholders... Mr. Holt’s compensation addresses the long-standing frustration of shareholders who want executive compensation directly tied to the creation of shareholder value... if the stock reaches $15/share, Mr. Holt will have created meaningful value for all shareholders, and he will be considerably and rightly rewarded."
Now here's why -- Holt's payday is tied to him delivering up to $15/share which the press release states: "will have created meaningful value for all shareholders"--What this means: Anything less than $15 is beneath the bar set by Alex which he believes delivers "meaningful value for all shareholders." Yes, the target is no less than $15 and potentially higher, even much higher.
I also disagree Holt's plan is the same as KM. Hardly. KM got incentives every year including Puerto Rico, remember? He had no skin in the game.
Denner advertises $6.677B BO price with the appointment of the new CEO whose compensation is tied to share price. And $15pps is probably the base price and it's clear he knows this amount will satisfy a majority of shareholders. Now here's the fun part. Now that HFs know this, it's entirely up to people like HF Alex and friends to drive that price and HFs come piling in seeing a 14x multiple announced today.